Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep573 | Endocrine-Related Cancer | ECE2022

Postoperative prediction of tumor recurrence in patients with nonfunctional pancreatic neuroendocrine tumors

Olearska Helena , Sowa-Staszczak Anna , Opalinska Marta , Kurzyńska Anna , Hubalewska-Dydejczyk Alicja

Introduction: Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group with various treatment options depending on grading, staging, and presence of symptoms related to hormonal secretion. Their incidence significantly increased over the past decade and nowadays constitutes 30% of all NETs of the gastrointestinal tract. Despite the evidence of a different malignancy potential of PNETs G2, postoperative management is the same in all patients. Ai...

ea0081p177 | Pituitary and Neuroendocrinology | ECE2022

Use of corrected SUVmax as a prognostic indicator of response to PRRT

Opalinska Marta , Sowa-Staszczak Anna , Kania-Kuc Adrian , Al Maraih Ibraheem , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Background: PRRT is an effective treatment option (especially for controlling disease progression)for disseminated neuroendocrine tumors (NETs), with good expression of the somatostatin receptors. Despite significant progress in NET personalized management, searching for novel predictive and prognostic factors of response to PRRT is crucial for more effective follow-up, better treatment choices leading to more favorable final outcome. Some recent studies indicate that the resp...

ea0090ep15 | Adrenal and Cardiovascular Endocrinology | ECE2023

A single center experience of extraadrenal paragangliomas–clinical and molecular analysis

Kurzyńska Anna , Opalinska Marta , Skalniak Anna , Rzepka Ewelina , Gilis-Januszewska Aleksandra , Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja

Paragangliomas are rare neuroendocrine neoplasms that arise from chromaffin tissue commonly located in the adrenal medulla, pre-aortic and paravertebral sympathetic plexus or skull base. About 30% of paragangliomas have a genetic basis. They may be associated with autosomal dominant inheritance of variants in the gene encoding succinate dehydrogenase or may coexist in genetically determined endocrine syndromes. The study aim was to analyse clinical and molecular data of patien...

ea0090ep27 | Adrenal and Cardiovascular Endocrinology | ECE2023

Metanephrines work-up in patients diagnosed with incindentaloma - the influence of commonly used drugs on results interpretation

Kokoszka Joanna , Opalinska Marta , Kolasa Magdalena , Szewczyk Monika , Sitarz Katarzyna , Bugajska Jolanta , Berska Joanna , Sztefko Krystyna , Hubalewska-Dydejczyk Alicja

Introduction: Due to the frequent occurrence of adrenal incidentalomas, diagnosis of their hormonal activity is a significant clinical concern. Approximately 7-10% of adrenal tumors are pheochromocytomas, which even in silent form can lead to hemodynamic instability during surgery. According to the ESE and ENSAT guidelines in any case of adrenal tumors greater than 1 cm pheochromocytoma should be excluded based on plasma metanephrines level and urinary metanephrines excretion....

ea0099p113 | Pituitary and Neuroendocrinology | ECE2024

2-[18F]FDG PET imaging biomarkers for clinical and metabolic assessment in ectopic cushing syndrome. increased spleen FDG uptake as a helpful parameter to predict the presence of metastases - a pilot study

Rzepka Ewelina , Kokoszka Joanna , Opalinska Marta , Sitarz Katarzyna , Grochowska Anna , Sowa-Staszczak Anna , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Introduction: 2-[18F]FDG PET/CT, commonly used for neoplastic lesions detection, also allows assessment of the severity of the inflammatory processes. Moreover, glucose uptake in spleen and bone marrow may be a useful biomarker of systemic inflammation. Patients with Cushing syndrome demonstrate many metabolic changes involving muscles and fat tissue. Some mechanisms are known, but their relationship to glucose metabolism is not well investigated. Our study aimed to correlate ...

ea0081p409 | Pituitary and Neuroendocrinology | ECE2022

Differences of clinical characteristics and treatment of sporadic and MEN-1 related insulinomas

Opalinska Marta , Gilis-Januszewska Aleksandra , Morawiec-Sławek Karolina , Rzepka Ewelina , Bogusławska Anna , Sowa Staszczak Anna , Hubalewska-Dydejczyk Alicja

Background: Although in most cases insulinomas are small and benign tumors, in about 4% they are malignant, mainly in course of inherited syndromes like MEN1, tubular sclerosis or neurofibromatosis type 1. While in case of benign tumors surgery is usually curative, the metastatic form brings difficulties in managing due to dissemination and the risk of recurring, life-threating, severe hypoglycemias. To elucidate the clinical differences between sporadic and MEN-1 linked insul...

ea0081ep764 | Pituitary and Neuroendocrinology | ECE2022

Clinical characteristics, treatment and outcomes of well-differentiated gastroenteropancreatic G3 NET

Opalinska Marta , Staszczak Anna Sowa , Kurzyńska Anna , Morawiec-Sławek Karolina , Stefańska Agnieszka , Hubalewska-Dydejczyk Alicja

Background: Although gastroenteropancreatic neuroendocrine tumors G3 (GEP-NET G3) and neuroendocrine cancers (GEP-NEC G3) are characterized in histopathological examination by Ki67>20% or >20 mitoses/10HPF their management and prognosis is substantially different. Despite the WHO introduces the novel well-differentiated neuroendocrine tumour of high grade (NET G3) classification in 2017 the clinical management of them is still challenging due to high NET G3 heterogenei...

ea0090p6 | Adrenal and Cardiovascular Endocrinology | ECE2023

Patients with NF1 need routine hormonal screening towards pheochromocytoma

Rzepka Ewelina , Bogusławska Anna , Kurzyńska Anna , Opalinska Marta , Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Up to 40% of pheochromocytoma cases have a genetic background. The prevalence of pheochromocytoma in neurofibromatosis type 1 (NF1) was reported to be from 0.1 to 5.7%. However, the actual incidence of pheochromocytoma in NF1 seems to be underestimated. Current recommendations on NF1 do not include systematic biochemical screening for the presence of pheochromocytoma. Our aim was to analyse clinicopathological characteristics of pheochromocytoma in the course of NF1 syndrome w...

ea0090ep608 | Endocrine-related Cancer | ECE2023

Mesenteric paraganglioma with a late-onset metastases accelerated after delayed surgery

Rzepka Ewelina , Minasyan Mari , Przybylik-Mazurek Elwira , Ulatowska-Białas Magdalena , Opalinska Marta , Sowa-Staszczak Anna , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Mesenteric paragangliomas are a rare entity; consequently, 20 cases have been reported to date. Although often found incidentally and considered benign, they have potential to metastasize. We present a case of 63-year old man with a 11-year history of the mesenteric paraganglioma. The lesion for the first time had been described on CT scan of the abdomen in 2010. However, the patient was lost to follow-up. In 2021 CT scan, followed by MRI of the abdomen, perfomed due to reccur...

ea0073aep509 | Pituitary and Neuroendocrinology | ECE2021

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

Opalinska Marta , Anna Kurzynska , Staszczak Anna Sowa , Joanna Palen-Tytko , Zwinczewska Helena , Karolina Morawiec-Slawek , Hubalewska-Dydejczyk Alicja

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...